December 31, 2008
(unaudited) Actual Actual Adjustment Adjusted Adjusted
GAAP GAAP Non-GAAP Non-GAAP
RMB US$ RMB RMB US$
Net Revenues:
EPIAO 39,326 5,764 39,326 5,764
TPIAO 16,373 2,400 16,373 2,400
Intefen 1,199 176 1,199 176
Inleusin 209 31 209 31
Iron 1,796 263 1,796 263
Export 1,148 168 1,148 168
Others 13 2 13 2
Total net revenues 60,064 8,804 60,064 8,804
Cost of revenues (5,622) (824) 110 (1) (5,512) (808)
Gross profit 54,442 7,980 54,552 7,996
Operating expenses
Research and
development
costs (12,439) (1,823) 7,110 (2) (5,329) (781)
Sales, marketing
and distribution
expenses (38,337) (5,619) 309 (1) (38,028) (5,574)
General and
administrative
expenses (5,960) (874) 825 (1) (5,135) (753)
Total operating
expenses (56,736) (8,316) (48,492) (7,108)
Operating (loss)
/income (2,294) (336) 6,060 888
Other income
/(expenses), net
Interest income 5,916 867 5,916 867
Grant income 107 16 107 16
Impairment loss on
available-for-sale
securities (4,391) (644) 4,391 (3) -- --
Others
'/>"/>SOURCE 3SBio Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Related biology technology :1.
3SBio Inc. Receives Official Recognition as a High-Tech Enterprise2.
3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 20093.
3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer4.
3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference5.
3SBio Inc. Announces Third Quarter 2008 Results6.
3SBio Inc. Files for SFDA Approval of NuLeusin7.
3SBio Inc. Announces Preliminary Third Quarter 2008 Results8.
3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 20089.
3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO10.
3SBio Inc. to Present at the UBS Global Life Sciences Conference11.
3SBio Inc. Announces Results of Annual General Meeting